research use only

Gliclazide Potassium Channel inhibitor

Name: Gliclazide
SKU: S2601
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S2601

Gliclazide(S1702, SE1702) is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC50 of 184 nM.

Chemical Structure

Molecular Weight: 323.41

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.96%

99.96

Related Targets	CD markers AChR Calcium Channel Sodium Channel GABA Receptor TRP Channel ATPase GluR NMDAR P2 Receptor Proton Pump P-gp CFTR SGLT Chloride Channel MCT Amino acid transporter GLUT CRM1 VDAC BCRP NKCC OCT NCX OAT VMAT Aquaporin EAAT GlyT GlyR
Related Products	Nicorandil TRAM-34 Sophocarpine ML133 HCl Hydralazine HCl Gliquidone PAP-1 VU0071063 Apamin A2793 Ajmaline A2764 dihydrochloride NS8593 Hydrochloride L-Palmitoylcarnitine chloride Cloperastine fendizoate ML277 Oxypeucedanin SKA-31 Butamben 1-EBIO DCPIB ICA-110381 JNJ 303 ML-297 ML213 NS6180 Senicapoc (ICA-17043) Nigericin ML365 NS3623

Chemical Information, Storage & Stability

Molecular Weight	323.41	Formula	C₁₅H₂₁N₃O₃S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	21187-98-4	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	S1702, SE1702			Smiles	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2

Solubility

In vitro
Batch:

DMSO : 65 mg/mL (200.98 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	Potassium channel ^[1] 184 nM

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04198948	Completed	Diabetes Mellitus Type 2	University of Sarajevo\|General Hospital Prim. Dr. Abdulah Nakas\|University of Dundee\|Wellcome Trust	March 4 2019	Phase 1
NCT03705195	Completed	Type 2 Diabetes Mellitus	University of Dundee\|NHS Tayside	August 3 2018	Not Applicable
NCT03467971	Completed	Healthy	Merck KGaA Darmstadt Germany	March 6 2018	Phase 1
NCT02643329	Completed	Healthy	Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited\|Chinese University of Hong Kong	January 2016	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):